Zantac Cancer Lawsuits Could Hinge On The Validity of Ranitidine Testing Methods
The question remains if Valisure caused the spike in NDMA by overheating their ranitidine test samples
Monday, July 11, 2022 - Four Zantac cancer bellwether trials have been scheduled starting on February 13, 2023, and running throughout the year that will set the stage for future trials or, hopefully, a swift and generous settlement offer. Sanofi, the maker of Zantac is accused along with co-defendant Chevron and others had covered up their knowledge of ranitidine, the main ingredient in Zantac 150, deteriorating in conditions of high heat to become N-nitrosodimethylamine, a deadly carcinogen. The bellwether title is an informal designation that suggests both sides to be particularly sensitive to jury reactions to the scientific facts. The Sanofi Zantac cancer scientific evidence could be particularly interesting in this case as both sides blame the other for being negligent. More than 125,000 former Zantac heartburn and acid reflux users have registered to file suit alleging that the heartburn medicine cancer they were diagnosed with was caused by regularly and repeatedly taking Zantac. Sanofi, on the other hand, thinks that online prescription drug testing lab Valisure may have overheated the ranitidine test samples to unnatural temperatures causing them to degrade into NDMA.
According to WebMD, David Light, CEO of Valisure declared "The ranitidine molecule itself is fundamentally unstable." The Federal government is weighing in saying that they are not sure about the ranitidine levels that Valisure claims but are being cautious when recalling ranitidine from the market. FDA tests showed NDMA levels only slightly higher than the 96 nanograms per tablet they figured would be safe. One such test simulated the 150-degree temperatures of a hot car for five days and found less than a 10% increase in NDMA above the threshold. The Department of Justice is also investigating Sanofi for potentially lying to government regulators about NDMA levels in ranitidine. Valisure online prescription drug testing labs found levels of NDMA orders of magnitude greater than the FDA allowance and filed a citizen's petition with the FDA to have ranitidine removed from the market, which the FDA complied with a few months later.
Zantac cancer lawyers continue to sign up potential plaintiffs that have used Zantac and developed certain types of cancer the court has ruled is specific to taking Zantac. Zantac cancers include bladder cancer, breast cancer, colorectal cancer, intestinal cancer, esophageal cancer, gastric cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, and prostate cancer. If you or a loved one have regularly taken Zantac and have been diagnosed with one of the above types of cancer you may qualify to file a claim. Zantac ranitidine is only one of several types of medicine capsules to have been found to have elevated levels of NDMA. The FDA has taken action or recalled several types of blood pressure medicine, diabetes medication, and smoking cessation drugs, adding credibility to the defense's assertion that the testing methods are unreliable. RAPS.org reported a study by the FDA that determined "No post-ingestion NDMA from ranitidine," eliminating the possibility that ranitidine turns into NDMA when it is exposed to stomach temperatures and acid conditions. ">
More Recent Heartburn MedicineLawsuit News:
- Zantac Cancer Trials Are In Discovery To Begin In October 2022 | 7/19/2022
- Zantac Cancer Bellwether Trials In California Could Set The Stage For A Global Settlement Offer | 7/5/2022
- The FDA Recommended Protein Pump Inhibitor Drugs Like Prilosec And Nexium That May Damage Health More Than Zantac | 6/23/2022
- Truck Drivers, Firefighters, and Police Officers May Have Taken More Zantac Than People In Other Occupations | 6/20/2022
- Scientists Are Expected To Confirm That Ranidine Causes Gastrointestinal Cancer With Slam Dunk Testimony | 6/9/2022
Lawyers for Zantac Heartburn Medicine Lawsuits
OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.